Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 37, Numéro 11, Novembre 2021
Nos jeunes pousses ont du talent !
|
|
|---|---|---|
| Page(s) | 1073 - 1076 | |
| Section | Partenariat médecine/sciences - Écoles doctorales - Masters | |
| DOI | https://doi.org/10.1051/medsci/2021168 | |
| Publié en ligne | 1 décembre 2021 | |
- Amirfakhryan H, Safari F. Outbreak of SARS-CoV2: pathogenesis of infection and cardiovascular involvement. Hellenic J Cardiol 2021; 62 : 13–23. [CrossRef] [PubMed] [Google Scholar]
- Bonny V, Maillard A, Mousseaux C, et al. Covid-19 : physiopathologie d’une maladie à plusieurs visages. Rev Med Interne 2020; 41 : 375–89. [CrossRef] [PubMed] [Google Scholar]
- D’Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of Covid-19 outbreak in Italy. Biosafety Health 2020; 2 : 57–9. [CrossRef] [Google Scholar]
- Pizzorno A, Padey B, Julien T, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Rep Med 2020; 1 : 100059. [CrossRef] [PubMed] [Google Scholar]
- Chen S, Einspanier R, Schoen J. Transepithelial electrical resistance (TEER): a functional parameter to monitor the quality of oviduct epithelial cells cultured on filter supports. Histochem Cell Biol 2015 ; 144 : 509–515. [CrossRef] [PubMed] [Google Scholar]
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9 : eaal3653. [CrossRef] [PubMed] [Google Scholar]
- Pizzorno A, Terrier O, Nicolas de Lamballerie C, et al. Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures. Front Immunol 2019 ; 10 : 60. [CrossRef] [PubMed] [Google Scholar]
- WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19. Interim WHO solidarity trial results. N Engl J Med 2021; 384 : 497–511. [CrossRef] [PubMed] [Google Scholar]
- Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMed 2021; 65 : 103255. [CrossRef] [Google Scholar]
- University of Aarhus. The impact of camostat mesilate on Covid-19 infection: an investigator-initiated randomized, placebo-controlled, phase IIa trial. Clinicaltrials.gov, 2021. [Google Scholar]
- Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for Covid-19. Viruses 2021; 13 : 628. [CrossRef] [PubMed] [Google Scholar]
- Falcone M, Tiseo G, Valoriani B, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe Covid-19 and role of variants of concern. Infect Dis Ther 2021; Aug 25, pp. 1–10, doi: 10.1007/s40121-021-00525-4. [Google Scholar]
- Meo SA, Bukhari IA, Akram J, et al. Covid-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci 2021; 25 : 1663–9. [PubMed] [Google Scholar]
- Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396 : 1979–93. [Google Scholar]
- Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397 : 881–91. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.